Predictive Biomarkers Market Report: Researching Growth and Sizing for Competitive Advantage
The global predictive biomarkers market is expected to register a revenue CAGR during the forecast period. Increase in number of clinical trials is a key factor driving market revenue growth during the forecast period. In addition, developments and advancements in this field are expanding. Approximately, 427,086 clinical studies are currently under trial globally. Predictive biomarkers are also utilized to identify patients who will benefit from adjuvant radio- and or chemotherapy. Predictive biomarkers can help with patient care decisions like choosing between different interventions or figuring out which patients would benefit from a particular treatment. For instance, Kirsten Ras (KRAS) is a frequently mutated oncogene in colorectal cancer and a predictive biomarker for Epidermal Growth Factor (anti-EGFR) monoclonal antibody therapy resistance. According to MD Anderson Cancer, KRAS mutations are among the most prevalent gene mutations associated with cancer, found in abou...